Merck gains FDA approval for Keytruda plus Trodelvy in first-line TNBC
Merck (NYSE:MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy (sacituzumab govitecan-hziy), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (CPS ≥10).






_1428024_640x360_2504714819594-640x360.webp&w=3840&q=75)

_1427966_640x360_2504712259590-640x360.webp&w=3840&q=75)


